# A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)

> **NCT02091752** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 3 (actual)

## Conditions studied

- Primary Myelofibrosis

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT02091752
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The study was terminated due to low enrollment.
- **Last updated:** 2016-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02091752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02091752, "A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02091752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*